Biodesix (BDSX) Payables (2019 - 2026)

Biodesix (BDSX) has 8 years of Payables data on file, last reported at $3.7 million in Q1 2026.

• Quarterly Payables rose 24.13% year-over-year to $3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.7 million (up 24.13% YoY) and the FY2025 annual result came in at $3.1 million, up 39.32% from the prior year.
• Payables rose to $3.7 million in Q1 2026, from $3.1 million in the prior quarter.
• In the past five years, Payables ranged from a high of $16.4 million in Q3 2022 to a low of $1.6 million in Q1 2023.
• A 5-year average of $4.2 million and a median of $3.0 million in 2023 frame the typical range for Payables.
• Annual changes were most pronounced in 2022 — Payables jumped 914.44% — and 2023, when it sank 82.03%.
• Tracing BDSX's Payables over 5 years: stood at $1.7 million in 2022, then surged by 71.86% to $3.0 million in 2023, then dropped by 25.67% to $2.2 million in 2024, then jumped by 39.32% to $3.1 million in 2025, then rose by 18.37% to $3.7 million in 2026.
• The last three Payables figures came in at $3.7 million (Q1 2026), $3.1 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.